Clinical trial
Study to Evaluate the Immune Response to Pneumococcal Vaccine in…
NCT00493324 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00493324 |
|---|---|
| Title | Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis |
| Official title | An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | alefacept, polyvalent pneumococcal vaccine |
| Enrollment | 43 |
| Start date | Jul 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jun 28, 2007 |
| Last update posted | Feb 2, 2012 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: